praliciguat
praliciguat: developed by 2 companies · 1 clinical trial tracked.
praliciguat evidence translation
What we can confirm
1 tracked trial
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about praliciguat, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Focal Segmental GlomerulosclerosisFocal Segmental Glomerulosclerosis (FSGS)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Akebia Therapeutics, Inc. (AKBA) | Phase 2 |
| Cyclerion Therapeutics, Inc. (CYCN) Focal Segmental Glomerulosclerosis (FSGS) | Approved |
Clinical Trials (1)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis
Primary endpoint: Change from Baseline in urine protein-to-creatinine ratio (UPCR)
InterventionalRandomizedtriple60 targetStarted 2025-12Completion 2028-0125 sites · United StatesAkebia Therapeutics
Frequently asked questions
Who is developing praliciguat?
praliciguat is being developed by Akebia Therapeutics, Inc., Cyclerion Therapeutics, Inc..
How many clinical trials involve praliciguat?
BioSniper tracks 1 clinical trial involving praliciguat.